Literature DB >> 8001587

Heterologous expression of the human D2S dopamine receptor in protease-deficient Saccharomyces cerevisiae strains.

P Sander1, S Grünewald, M Bach, W Haase, H Reiländer, H Michel.   

Abstract

The cDNA for the human D2S dopamine receptor has been functionally expressed in the unicellular yeast Saccharomyces cerevisiae. The original D2S gene and an elongated D2S gene with an N-terminal fusion to the first 24 amino acids of the STE2 gene from S. cerevisiae were introduced into the episomal yeast expression vector YEp51 under the control of the GAL10 promoter. Expression studies performed in a wild-type strain and in two protease-deficient strains of S. cerevisiae revealed that the receptor was functionally expressed with respect to its ligand-binding properties. The KD values for the binding of the dopamine antagonist [3H]spiperone were calculated to be 1.6 nM for the D2S receptor alone and 1.9 nM for the STE2-D2S chimaera. Both membrane proteins could be further characterized by ligand-displacement studies using certain dopamine agonists and antagonists. D2S dopamine-receptor-specific polyclonal antibodies were used to monitor the heterologous expression of the receptor. Western-blot analysis of membranes prepared from transformed yeast cells producing either the receptor protein alone or the receptor fusion protein revealed apparent molecular masses of 40 kDa (D2S receptor alone) and 42 kDa (STE2/D2S receptor fusion protein). It could be shown that, in comparison to the expression in a wild-type S. cerevisiae strain, the amount of receptor degradation was drastically reduced in the protease-deficient strains. The localizations of the heterologously produced dopamine receptor and of the chimaera in the recombinant yeast were studied by immunogold electron microscopy and were found to be restricted mainly to the vacuole of the cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8001587     DOI: 10.1111/j.1432-1033.1994.tb20098.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  7 in total

1.  In vitro assay using engineered yeast vacuoles for neuronal SNARE-mediated membrane fusion.

Authors:  Young-Joon Ko; Miriam Lee; KyeongJin Kang; Woo Keun Song; Youngsoo Jun
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-12       Impact factor: 11.205

Review 2.  Current strategies for protein production and purification enabling membrane protein structural biology.

Authors:  Aditya Pandey; Kyungsoo Shin; Robin E Patterson; Xiang-Qin Liu; Jan K Rainey
Journal:  Biochem Cell Biol       Date:  2016-01-20       Impact factor: 3.626

3.  Genetic and physical interactions involving the yeast nuclear cap-binding complex.

Authors:  P Fortes; J Kufel; M Fornerod; M Polycarpou-Schwarz; D Lafontaine; D Tollervey; I W Mattaj
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

4.  Comparative biochemical and pharmacological characterization of the mouse 5HT5A 5-hydroxytryptamine receptor and the human beta2-adrenergic receptor produced in the methylotrophic yeast Pichia pastoris.

Authors:  H M Weiss; W Haase; H Michel; H Reiländer
Journal:  Biochem J       Date:  1998-03-15       Impact factor: 3.857

5.  Functional characterization of an alpha-factor-like Sordaria macrospora peptide pheromone and analysis of its interaction with its cognate receptor in Saccharomyces cerevisiae.

Authors:  Severine Mayrhofer; Stefanie Pöggeler
Journal:  Eukaryot Cell       Date:  2005-04

6.  Progress toward heterologous expression of active G-protein-coupled receptors in Saccharomyces cerevisiae: Linking cellular stress response with translocation and trafficking.

Authors:  Michelle A O'Malley; J Dominic Mancini; Carissa L Young; Emily C McCusker; David Raden; Anne S Robinson
Journal:  Protein Sci       Date:  2009-11       Impact factor: 6.725

Review 7.  Engineering G protein-coupled receptor signalling in yeast for biotechnological and medical purposes.

Authors:  Bettina Lengger; Michael K Jensen
Journal:  FEMS Yeast Res       Date:  2020-02-01       Impact factor: 2.796

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.